Cancer and Leukemia Group B

CALGB Cancer and Leukemia Group B (an alliance of cancer centers that conducts national clinical trials in cancer) CD cluster of differentiation... [Pg.1383]

Clin Pharmacol Ther 1991 50 573-579. Ratain MJ, Rosner G, Allen SL et al. Population pharmacodynamic study of amonafide a Cancer and Leukemia Group B study J Clin Oncol 1995 13 741-747. [Pg.307]

Bums, C. P., Halabi, S., Qamon, G. H., Hars, V., Wagner, B. A., Hohl, R. J., Lester, E., Kirshner, J. J., Vindguerra, V., and Paskett, E., 1999, Phase 1 chnical study offish oil fatty acid capsules for patients with cancer cachexia cancer and leukemia group B study 9473, Clin. CancerRes. 5 3942-3947. [Pg.116]

Kontermann RE (2006) Immunohposomes for cancer therapy. Curr Opin Mol Ther 8 39-45 Kombhth AB, Herndon JEII, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC (2002) Impact of azacytidine on the quality of hfe of patients with myelodysplastic syndrome treated in a randomized phase III trial A cancer and leukemia group B smdy. J Chn Oncol 20 2441— 2452 Kouzarides T (2000) Acetylation A regulatory modification to rival phosphorylation EMBO J 19 1176-1179... [Pg.424]

Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage Ilia non-small cell carcinoma of the lung report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992 10 1237-1244. [Pg.62]

Gy of radiation to the pancreas was tolerable in pancreatic cancer patients with a 20% response rate in 15 evaluable patients. Three out of eight patients with a minimum of 12 mo follow up were alive (65). Based on these data, Cancer and Leukemia Group B (CALGB) conducted a phase II trial to examine the efficacy of concurrent twice-weekly Gemcitabine (40 mg/m2) and radiation (50.4 Gy) treatment regimen in patients with locally advanced pancreatic cancer. The preliminary result showed 55% of the... [Pg.119]

CALGB, Cancer and Leukemia Group B LCSG, Lung Cancer Study Group MVP, mitomycin/ vinblastine/cisplatin VP, vinblastine/cisplatin RT, radiation therapy. [Pg.182]

Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage M non-small cell lung cancer Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. JNatl Cancer Inst 1996 88 1210-1215. [Pg.193]

Clamon G. Herndon J. Cooper R, et al. Radiosensitization with carboplatin forpatients with unresectable stage III non-small-cell lung cancer A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group J Clin Oncol 1999 17 4—11. [Pg.194]

Perry MC, Herndon JE, Eaton WL, et al. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer an update of Cancer and Leukemia Group B study 8083. J Clin Oncol 1998 16 2466-2467. [Pg.212]

L5. Larson, R. A., Dodge, R. K., Burns, C. P., Lee, E. J., Stone, R. M., Schulman, P., Duggan, D., Davey, F. R., Sobol, R. E., Frankel, S. R., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia Cancer and leukemia group B study 8811. Blood 85, 2025-2037 (1995). [Pg.342]

Samuels BL, Hollis DR, Rosner GL, et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen a cancer and leukemia group B study. Clin Cancer Res 1997 3(11) 1977—1984. [Pg.425]

Lee EJ, George SL, Caligiuri M, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia results of cancer and leukemia group B study 9420. J Clin Oncol 1999 17(9) 2831-2839. [Pg.426]

Hensley ML, Peterson B, Silver RT, Larson RA, Schiffer CA, Szatrowski TP. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 2000 18(6) 1301-8. [Pg.710]

Booth BW, Kotzun AH, Weiss RB, Ehison RR, Budman D, Khojasteh A, Wood W. Phase II trial of acivicin in advanced breast carcinoma a Cancer and Leukemia Group B Study. Cancer Treat Rep 1986 70(10) 1247-8. [Pg.32]

Eastham JA, Kelly WK, Grossfeld GD, Small EJ Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203 a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003 62(Suppl l) 55-62. [Pg.78]

Eastham JA, Kelly WK, Grossfeld GD, Small EJ Cancer and Leukemia Group B. Cancer and Leukemia Group B... [Pg.79]

Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei E 3rd. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998 90(16) 1205-11. [Pg.255]

Miller AA, Herndon JE 2nd, Hollis DR, Ellerton J, Langleben A, Richards F 2nd, Green MR. Schedule dependency of 21-day oral versus 3-day intravenous etopo-side in combination with intravenous cisplatin in extensive-stage small-ceU lung cancer a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995 13(8) 1871-9. [Pg.1042]

Hargis JB, Anderson JR, Propert KJ, Green MR, Van Echo DA, Weiss RB. Predicting genitourinary toxicity m patients receiving cisplatin-based combination chemotherapy a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 1992 30(4) 291-6. [Pg.2870]

Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol 2002 20(16) 3369-75. [Pg.3253]

Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE 3rd, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2 report of cancer and leukemia group B 9661. Clin Cancer Res 2002 8(12) 3718-27. [Pg.3481]

Westbrook CA, Hooberman AL, Spino C> Dodge RK, Larson RA, Davey F, et al. Clinical significance on the BCR-ABL fusion gene in adult acute lymphoblastic leukemia a Cancer and Leukemia Group B Study (8762). Blood 1992 80 2983-90. [Pg.1481]

Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction cancer and leukemia group B 9565. J Chn Oncol 2000 18 2780-2787. [Pg.2326]

Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J CUn Oncol 2003 21 1431-1439. [Pg.2363]

Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and OS in adult patients with de novo acute myeloid leukemia results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002 100 4325-4336. [Pg.2507]

Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphoblastic leukemia results of cancer and leukemia group B study 9251. J Clin Oncol 2001 19 4014-4022. [Pg.2507]

Baer MR, George SL, Dodge RK. Phase 3 study of the multidrug resistance modulator PS C-83 3 in previously untreated patients 60 years of age and older with acute myeloid leukemia Cancer and Leukemia Group B Study 9720. Blood 2002 100 1224-1232. [Pg.2510]

Byrd JC, Peterson BL, Morrison VL, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with ritux-imab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia Results from Cancer and Leukemia Group B 9712. Blood 2003 101 6-14. [Pg.2524]

R. L. Capizzi, R. Davis, B. Powell, et al. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia—a cancer and leukemia group B study. J. Clin. Oncol. 6 499 (1988). [Pg.255]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...